Prostacyclin
Links shared publicly online about this topic
Emergency Med Medical News about Kidney Failure
mdlinx.com — “Heparin versus prostacyclin in continuous hemodiafiltration for acute renal failure: Effects on platelet function in the systemic circulation and across the filter” View full resource at mdlinx.com
Most Recently Shared on June 12, 2010 at 7:39 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Heparin versus prostacyclin in continuous hemodiafiltration for acute renal failure: Effects on platele... http://bit.ly/afR3GI #ER #mdlinx
Family Medicine Article | Nitric Oxide
mdlinx.com — “Beneficial vasoactive endothelial effects of fluvastatin: focus on prostacyclin and nitric oxide” View full resource at mdlinx.com
Most Recently Shared on January 12, 2011 at 7:10 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Beneficial vasoactive endothelial effects of fluvastatin: focus on prostacyclin and nitric oxide: H... http://bit.ly/gSi2cC #FamPractice
Cardiology News & Articles - MDLinx - Hypertension on #MDlinx
mdlinx.com — “Cardiology News & Articles - MDLinx - Hypertension on #MDlinx” View full resource at mdlinx.com
Most Recently Shared on July 21, 2010 at 9:25 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Prostacyclin administration errors in pulmonary arterial hypertension patients admitted to hospital... http://bit.ly/9tORk8 #cardio #mdlinx
index -
www1.actelion.com — “Actelion is a global, independent biopharmaceutical company discovering, developing and marketing innovative drugs for high unmet medical needs. Find here the latest news & events.” View full resource at www1.actelion.com
Most Recently Shared on July 20, 2009 at 4:05 pm By:
Dr. Warren Rosenblum Physician, Doctor, Internist, and Cardiologist
New oral prostacyclin showed favorable effects in Phase IIa trial, now to enter Phase III trials. http://tinyurl.com/npgl3y
Tyvaso approved for pulmonary arterial hypertension (PAH) - MPR
empr.com — “The FDA has approved Tyvaso (treprostinil inhalation solution, from United Therapeutics), a prostacyclin vasodilator, for the treatment of pulmonary arterial hypertension (PAH) using the Tyvaso Inhalation System.” View full resource at empr.com
Most Recently Shared on July 30, 2009 at 8:18 pm By:
MPR News: Tyvaso approved for pulmonary arterial hypertension (PAH): The FDA has approved Tyvaso (trepr.. http://bit.ly/UGQxc
Arena Pharmaceuticals Initiates Phase 1 Clinical Trial Of APD811 For Pulmonary Arterial Hypertension - QualityPoint Technologies
qualitypointtech.net — “Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced the initiation of dosing in a Phase 1 clinical trial of APD811, a novel oral drug candidate discovered by Arena that targets the prostacyclin receptor for the treatment of pulmonary arterial hypertension, or PAH.” View full resource at qualitypointtech.net
Most Recently Shared on December 11, 2010 at 2:04 pm By:
Arena Pharmaceuticals Initiates Phase 1 Clinical Trial Of APD811 For Pulmonary Arterial Hypertension: Arena Pharma... http://bit.ly/fS61b2
Arena initiates dosing in APD811 Phase 1 clinical trial for pulmonary arterial hypertension
news-medical.net — “Arena Pharmaceuticals, Inc. announced today the initiation of dosing in a Phase 1 clinical trial of APD811, a novel oral drug candidate discovered by Arena that targets the prostacyclin receptor for the treatment of pulmonary arterial hypertension, or PAH.” View full resource at news-medical.net
Most Recently Shared on December 10, 2010 at 2:26 pm By:
Arena initiates dosing in APD811 Phase 1 clinical trial for pulmonary arterial hypertension: Arena Pharmaceutica... http://bit.ly/dYzsFz
Increased strength formulation of Ventavis launched - MPR
empr.com — “Actelion Pharmaceuticals has launched an increased strength formulation of Ventavis (iloprost inhalation solution), an inhaled prostacyclin analogue, for the treatment of pulmonary arterial hypertension (WHO Group I) in patients with New York Heart Association (NYHA) Class III or IV symptoms.” View full resource at empr.com
Most Recently Shared on September 2, 2009 at 2:22 pm By:
MPR News: Increased strength formulation of Ventavis launched: Actelion Pharmaceuticals has launched an.. http://bit.ly/15RRLU
Estrogen protects against cardiovascular disease
physorg.com — “(PhysOrg.com) -- UCD researchers led by Conway Fellow, Professor Therese Kinsella have shown that estrogen can protect against cardiovascular disease by impacting the levels of a key protein called prostacyclin receptor. The findings are published today in the Journal of Molecular Biology.” View full resource at physorg.com
Most Recently Shared on February 24, 2010 at 8:07 pm By:
PhysOrg Health News Health News
Estrogen protects against cardiovascular disease http://tw.physorg.com/186246325
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Sandeep Pulim MD
Over 2K medical journal articles & health news summarized and delivered FREE to 35 specialties daily. Oncology, Rheumatology, Cardiology, Neurology, Psychiatry
-
Sandeep Pulim MD
Over 2K medical journal articles & health news summarized and delivered FREE to 35 specialties daily. Oncology, Rheumatology, Cardiology, Neurology, Psychiatry
-
Sandeep Pulim MD
Over 2K medical journal articles & health news summarized and delivered FREE to 35 specialties daily. Oncology, Rheumatology, Cardiology, Neurology, Psychiatry
Advertisement
